| Name | Title | Contact Details |
|---|
Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.
Eli Lilly and Company is a global pharmaceutical corporation based in Indianapolis, Indiana, with a history of nearly 150 years. Founded in 1876 by Colonel Eli Lilly, the company has grown to become one of the largest pharmaceutical enterprises in the world, employing over 42,900 people as of 2023. Lilly focuses on biomedical research, drug discovery, and manufacturing, with a diverse portfolio that includes treatments for diabetes, oncology, neuroscience, and immunology. Lilly pioneered the first commercially available insulin product in 1923 and continues to innovate with modern offerings like Trulicity and Mounjaro for diabetes management. The company also develops drugs such as Verzenio for breast cancer and Zyprexa for psychiatric disorders. With a strong emphasis on research and development, Lilly is recognized for its commitment to improving drug accessibility and patient care through partnerships with healthcare providers and systems worldwide.
PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.
ILiAD Biotechnologies, LLC manufactures vaccines for the prevention and treatment of disease caused by Bordetella Pertussis.
Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.